# Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis

Study · id `cardio:ct-nct04968509` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04968509](<https://clinicaltrials.gov/study/NCT04968509>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04968509

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT04968509. Randomized; single masking; primary purpose treatment. Start 2024-03-22 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT04968509, source copy `cardio:ctgov-nct04968509-2024-05-09`, retrieved 2026-10-26)
- Started: 2024-03-22 (actual) (ClinicalTrials.gov record NCT04968509, source copy `cardio:ctgov-nct04968509-2024-05-09`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT04968509, source copy `cardio:ctgov-nct04968509-2024-05-09`, retrieved 2026-10-26)
- Completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT04968509, source copy `cardio:ctgov-nct04968509-2024-05-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04968509, source copy `cardio:ctgov-nct04968509-2024-05-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04968509-2024-05-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis
- Condition: Aortic Stenosis
- Intervention (Drug): PCSK9 inhibitors and statins with or without ezetimibe
- Intervention (Drug): Statins with or without ezetimibe
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER
- Collaborator: Beijing Municipal Health Commission
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)
- Registry lists this organization as a collaborator: Beijing Municipal Health Commission (`cardio:org-beijing-municipal-health-commission`)

## Provenance

Content hash: c4301892cf755d77d45591023e0aed0a27783c1def88e61fa798f57c445298c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
